Q32 Bio annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Q32 Bio Free Cash Flow (FCF) History (QTTB)
Q32 Bio reported −$33.5M in free cash flow for fiscal 2025, an increase of $34.2M from the previous fiscal year, with a free cash flow margin of −62.42%.
View full Q32 Bio company overviewQ32 Bio free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$33.5M | $34.2M | — | −62.42% |
| 2024 | 2024-12-31 | −$67.8M | −$49.1M | — | — |
| 2023 | 2023-12-31 | −$18.7M | $96.3M | — | −1616.09% |
| 2022 | 2022-12-31 | −$114.9M | −$2.8M | — | −3583.10% |
| 2021 | 2021-12-31 | −$112.1M | −$14.1M | — | −330.13% |
| 2020 | 2020-12-31 | −$98.1M | $15.1M | — | −3629.35% |
| 2019 | 2019-12-31 | −$113.2M | −$45.7M | — | −6794.18% |
| 2018 | 2018-12-31 | −$67.5M | −$72.0M | — | −1268.34% |
| 2017 | 2017-12-31 | $4.5M | — | — | — |
Q32 Bio quarterly free cash flow
Q1.17
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q3.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$4.2M | $15.3M | — | — |
| Q4 2024 | 2024-12-31 | −$11.4M | −$715,000 | — | — |
| Q3 2024 | 2024-09-30 | −$19.6M | −$35.5M | — | — |
| Q2 2024 | 2024-06-30 | −$22.2M | −$10.9M | — | — |
| Q1 2024 | 2024-03-31 | −$14.6M | −$2.0M | — | — |
| Q4 2023 | 2023-12-31 | −$10.7M | $16.5M | — | — |
| Q3 2023 | 2023-09-30 | $15.9M | $40.8M | — | — |
| Q2 2023 | 2023-06-30 | −$11.4M | $19.6M | — | −3211.30% |
| Q1 2023 | 2023-03-31 | −$12.5M | $19.3M | — | −1558.73% |
| Q4 2022 | 2022-12-31 | −$27.2M | $3.6M | — | −3392.52% |
| Q3 2022 | 2022-09-30 | −$24.9M | $926,000 | — | −3109.48% |
| Q2 2022 | 2022-06-30 | −$31.0M | −$6.1M | — | −3861.22% |
| Q1 2022 | 2022-03-31 | −$31.8M | −$1.2M | — | −3969.20% |
| Q4 2021 | 2021-12-31 | −$30.8M | −$18.2M | — | −3836.41% |
| Q3 2021 | 2021-09-30 | −$25.9M | $3.2M | — | −1542.28% |
| Q2 2021 | 2021-06-30 | −$24.9M | $3.7M | — | −1137.40% |
| Q1 2021 | 2021-03-31 | −$30.6M | −$2.8M | — | −104.56% |
| Q4 2020 | 2020-12-31 | −$12.6M | $17.5M | — | −1282.35% |
| Q3 2020 | 2020-09-30 | −$29.0M | −$1.8M | — | −5122.40% |
| Q2 2020 | 2020-06-30 | −$28.6M | −$986,000 | — | −5039.68% |
| Q1 2020 | 2020-03-31 | −$27.9M | $458,000 | — | −4741.33% |
| Q4 2019 | 2019-12-31 | −$30.1M | −$6.0M | — | −5338.90% |
| Q3 2019 | 2019-09-30 | −$27.2M | −$8.7M | — | −6169.39% |
| Q2 2019 | 2019-06-30 | −$27.6M | −$14.7M | — | −7038.01% |
| Q1 2019 | 2019-03-31 | −$28.3M | −$16.3M | — | −10495.19% |
| Q4 2018 | 2018-12-31 | −$24.0M | — | — | −2007.44% |
| Q3 2018 | 2018-09-30 | −$18.5M | −$12.8M | — | −1155.87% |
| Q2 2018 | 2018-06-30 | −$12.9M | — | — | −924.44% |
| Q1 2018 | 2018-03-31 | −$12.1M | −$6.7M | — | −1069.88% |
| Q3 2017 | 2017-09-30 | −$5.7M | — | — | — |
| Q1 2017 | 2017-03-31 | −$5.4M | — | — | — |
Q32 Bio free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$98.1M to −$33.5M, a net increase of $64.5M. Q32 Bio's latest reported quarter, Q3 2025, generated −$4.2M in free cash flow, an increase of $15.3M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Q32 Bio source filings ↗Community posts
Q32 reports maintained hair-growth responses after treatment withdrawal
Q32 Bio ($QTTB) reported new off-treatment follow-up from the open-label Part B of its SIGNAL-AA study of bempikibart for severe alopecia areata. Among 12 patients who had shown hair growth by the end of 36 weeks of treatment and entered fo ...
